Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $396 to $405.